Dean Capital Investments Management LLC acquired a new stake in shares of InMode Ltd. (NASDAQ:INMD) during the third quarter, according to its most recent Form 13F filing with the SEC. The fund acquired 44,216 shares of the healthcare company’s stock, valued at approximately $951,000. InMode accounts for about 0.6% of Dean Capital Investments Management LLC’s investment portfolio, making the stock its 13th biggest holding. Dean Capital Investments Management LLC owned approximately 0.14% of InMode at the end of the most recent reporting period.
A number of other institutional investors also recently modified their holdings of the business. Optimum Investment Advisors purchased a new stake in shares of InMode in the 3rd quarter worth about $28,000. Patriot Financial Group Insurance Agency LLC purchased a new stake in shares of InMode in the 3rd quarter worth about $32,000. Tower Research Capital LLC TRC purchased a new stake in shares of InMode in the 3rd quarter worth about $43,000. Steward Partners Investment Advisory LLC purchased a new stake in shares of InMode in the 3rd quarter worth about $122,000. Finally, Alpine Woods Capital Investors LLC purchased a new stake in shares of InMode in the 3rd quarter worth about $399,000. 1.07% of the stock is currently owned by institutional investors and hedge funds.
InMode stock traded up $0.99 during mid-day trading on Tuesday, reaching $46.40. The stock had a trading volume of 11,615 shares, compared to its average volume of 1,144,156. The company’s 50-day moving average price is $28.42. InMode Ltd. has a one year low of $13.06 and a one year high of $46.24. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.83 and a quick ratio of 7.47.
INMD has been the topic of a number of recent research reports. UBS Group initiated coverage on shares of InMode in a research report on Tuesday, September 3rd. They issued a “buy” rating and a $28.00 target price on the stock. Barclays upped their target price on shares of InMode from $27.00 to $45.00 and gave the stock an “overweight” rating in a research report on Wednesday, November 6th. Robert W. Baird reaffirmed an “outperform” rating and issued a $45.00 target price (up from $27.00) on shares of InMode in a research report on Wednesday, November 6th. Canaccord Genuity started coverage on shares of InMode in a research report on Tuesday, September 3rd. They issued a “buy” rating and a $30.00 target price on the stock. Finally, Zacks Investment Research upgraded shares of InMode from a “hold” rating to a “strong-buy” rating and set a $45.00 price target on the stock in a research note on Friday. Four investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $38.60.
InMode Company Profile
InMode Ltd. designs, develops, manufactures, and markets minimally-invasive aesthetic medical products based on its proprietary radio frequency assisted lipolysis and deep subdermal fractional radio frequency technologies. The company offers minimally-invasive aesthetic medical products for procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments.
Read More: Diversification For Individual Investors
Want to see what other hedge funds are holding INMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for InMode Ltd. (NASDAQ:INMD).
Receive News & Ratings for InMode Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InMode and related companies with MarketBeat.com's FREE daily email newsletter.